# Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis

> **NCT03793010** · PHASE3 · TERMINATED · sponsor: **Pacira Pharmaceuticals, Inc** · enrollment: 70 (actual)

## Conditions studied

- Osteoarthritis, Hip

## Interventions

- **DRUG:** FX006
- **DRUG:** Normal saline

## Key facts

- **NCT ID:** NCT03793010
- **Lead sponsor:** Pacira Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-12
- **Primary completion:** 2019-08-07
- **Final completion:** 2019-08-07
- **Target enrollment:** 70 (ACTUAL)
- **Why stopped:** By Sponsor due to occurrences of incomplete study drug administration
- **Last updated:** 2024-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03793010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03793010, "Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03793010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*